Confronto

Enfuvirtid vs. Linaclotid

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Ricerca (altro)

N. CAS

159519-65-0

851199-59-2

Peso molecolare

4491.88 g/mol

1526.74 g/mol

Emivita

nessun dato

Sequenza

nessun dato

Meccanismo d'azione

Enfuvirtid

Enfuvirtide binds the first heptad-repeat region (HR1) of the gp41 subunit of the HIV envelope protein. This prevents the conformational change required for fusion of the viral and cell membranes — the virus cannot enter the cell.

Linaclotid

Linaclotide activates the guanylate cyclase-C receptor on the luminal surface of the intestinal epithelium. This raises cyclic GMP (cGMP), increases secretion of chloride and bicarbonate into the lumen, raises stool fluid content and accelerates transit; pain signaling is also modulated.

Base di evidenze

Evidenza più alta

RCT sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	Enfuvirtid	Linaclotid
Germania	Su prescrizione	Su prescrizione
Stati Uniti	Su prescrizione	Su prescrizione

Voci complete

Frequently asked questions

What is the difference between Enfuvirtid and Linaclotid?: Enfuvirtid is classified as "Ricerca (altro)", while Linaclotid is classified as "Ricerca (altro)". Enfuvirtid: Enfuvirtide is a synthetic 36-amino-acid peptide and the first HIV-1 fusion inhibitor. It binds the HR1 region of the viral envelope protein gp41, blocking viral entry into the cell. Approved for treatment-experienced HIV patients. Linaclotid: Linaclotide is a 14-amino-acid peptide and guanylate cyclase-C (GC-C) agonist. It is approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Enfuvirtid or Linaclotid?: The highest available evidence level is "RCT sull'uomo" for Enfuvirtid and "RCT sull'uomo" for Linaclotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Enfuvirtid and Linaclotid in Germany and the United States?: Germania: Enfuvirtid — Su prescrizione, Linaclotid — Su prescrizione. Stati Uniti: Enfuvirtid — Su prescrizione, Linaclotid — Su prescrizione. These are factual summaries with source and review date on the individual pages.

Country

Enfuvirtid

Linaclotid

Germania

Su prescrizione

Stati Uniti

Su prescrizione

Frequently asked questions

What is the difference between Enfuvirtid and Linaclotid?

Enfuvirtid is classified as "Ricerca (altro)", while Linaclotid is classified as "Ricerca (altro)". Enfuvirtid: Enfuvirtide is a synthetic 36-amino-acid peptide and the first HIV-1 fusion inhibitor. It binds the HR1 region of the viral envelope protein gp41, blocking viral entry into the cell. Approved for treatment-experienced HIV patients. Linaclotid: Linaclotide is a 14-amino-acid peptide and guanylate cyclase-C (GC-C) agonist. It is approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Enfuvirtid or Linaclotid?

The highest available evidence level is "RCT sull'uomo" for Enfuvirtid and "RCT sull'uomo" for Linaclotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Enfuvirtid and Linaclotid in Germany and the United States?

Germania: Enfuvirtid — Su prescrizione, Linaclotid — Su prescrizione. Stati Uniti: Enfuvirtid — Su prescrizione, Linaclotid — Su prescrizione. These are factual summaries with source and review date on the individual pages.